Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cediranib Hodgkins Lymphoma	M.D. Anderson Cancer Center	P3	BB (66)
Ceralasertib Non-Small Cell Lung Carcinoma	Mario Negri Institute for Pharmacological Research	P3	BB (66)
Cetuximab Rectum Adenocarcinoma	Sixth Affiliated Hospital, Sun Yat-sen University	P3	BB (66)
Cetuximab Head And Neck Cancer	Pfizer	P3	BB (66)
Cetuximab Rectal Cancer	Fudan University	P3	BB (66)
Chlorambucil MALT Lymphoma	International Extranodal Lymphoma Study Group (IELSG)	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Adenosquamous Lung Carcinoma	Barbara Ann Karmanos Cancer Institute	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Non-Small Cell Squamous Lung Carcinoma	Gruppo Oncologico Italiano di Ricerca Clinica	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Anal Carcinoma	Federation Francophone de Cancerologie Digestive	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Biliary Tract Cancer	Merck Sharp & Dohme LLC	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Diffuse Large B-Cell Lymphoma	Dipenkumar Modi	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Ovarian Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Fallopian Tube Cancer	GOG Foundation	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Fallopian Tube Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Fallopian Tube Carcinoma	Mayo Clinic	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Gastroesophageal Junction Adenocarcinoma	Shenyang Sunshine Pharmaceutical Co., LTD.	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Urethra Transitional Cell Carcinoma	Nagoya University	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Ovarian Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BB (66)
Cis-Diamminedichloroplatinum Ii Triple-Negative Breast Carcinoma	Andrew Hantel, MD	P3	BB (66)
Concizumab Hemophilia A	Novo Nordisk A/S	P3	BB (66)
Crisugabalin Postherpetic Neuralgia	Haisco Pharmaceutical Group Co., Ltd.	P3	BB (66)
cs0159 Primary Biliary Cholangitis	Cascade Pharmaceuticals, Inc	P3	BB (66)
Cyclophosphamide Acute Biphenotypic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P3	BB (66)
Cyclophosphamide Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)	Sumithira Vasu	P3	BB (66)
Cyclophosphamide Urinary Bladder Carcinoma	Beijing Biotech	P3	BB (66)

Showing 2151 to 2175 of 42,301 assets

PreviousPage 87 of 1693Next